Bao 2020b.

Study characteristics
Methods	Trial design: case report  Type of publication: epub, ahead of print  Setting: hospital Recruitment dates: 16 February‐19 March 2020 Country: China Language: English Number of centres: 1 Trial registration number: NR Date of registration: NR
Participants	Age: 38 Gender: male Ethnicity: NR Number of participants (recruited/allocated/evaluated): 1 Severity of disease: severe Co‐morbidities: nil  Inclusion criteria: NR Exclusion criteria: NR Previous treatments (e.g. experimental drug therapies, oxygen therapy, ventilation): NR
Interventions	CP therapy or hyperimmune immunoglobulin therapy: CP therapy Details of CP: Type of plasma: ABO‐compatible  Volume: 150ml to 200 mL each dose Number of doses: 2 Antibody test and antibody‐titre: NR Pathogen inactivated or not: NR RT‐PCR tested: NR Details of donors: Gender: NR HLA and HNA antibody‐negative: NR Severity of disease: NR Timing from recovery from disease: NR RT‐PCR tested: NR Treatment details, including time of plasma therapy (e.g. early stage of disease): administered between 9 and 24 days after admission For studies including a control group: comparator (type): not applicable Concomitant therapy: antibiotics, haemostatic drugs were administered, low‐temperature noradrenaline dilution solution and low‐temperature thrombin solution, antifungals, antivirals, tracheostomy, ventilation, craniotomy, mannitol Duration of follow‐up: up to 32 days Treatment cross‐overs: not applicable Compliance with assigned treatment: not applicable
Outcomes	Primary study outcome(s): NR Primary review outcomes All‐cause mortality at hospital discharge: reported Time to death: not applicable Secondary review outcomes Number of participants with grade 3 and grade 4 AEs, including potential relationship between intervention and adverse reaction (e.g. TRALI, transfusion‐transmitted infection, TACO, TAD, acute transfusion reactions): NR Number of participants with SAEs: NR Improvement of clinical symptoms, assessed through need for respiratory support at up to 7 days; 8‐15 days; 16‐30 days: reported 30‐day and 90‐day mortality: not applicable Admission to the ICU: reported Length of stay on the ICU: NR Time to discharge from hospital: NR  QoL: NR Additional study outcomes: NR
Notes	Sponsor/funding: no funding received COIs: all study authors declare no competing interests Other: nil